NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA338

Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA338

1.1 Pomalidomide, in combination with dexamethasone, is not recommended within its marketing authorisation for treating relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy.

1.2 People whose treatment with pomalidomide was started within the NHS before this guidance was published should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

 

http://www.nice.org.uk/guidance/ta338

Site by Devopa
© Copyright 2020 NHS. All rights reserved.